AURINIA PHARMACEUTICALS INC
AUPHNASDAQ🏆 #1673 by market capEarnings Nov 3US Equity
$410.91▼ $15.12 (−3.68%)
Simulated price1h—
24h▼ 3.7%
7d—
14d—
30d—
1y—
🏦Market Cap
$1.99B
Small Cap
📈Revenue Growth (YoY)
+20.6%
Healthy
📊Gross Margin
89.7%
High
💵FCF Margin
55.9%
Strong
⚖️P/S Ratio
6.7x
Fair
Otter Score
49
Weak
📊
Analyst Ratings
Price
$410.91
Total
15
Raised
1
Lowered
4
Avg PT
$16.00
H / L
$16 / $16
| Institution | Action | Rating | Date |
|---|---|---|---|
Leerink Partners | Downgraded | Outperform → Market Perform | 2025-12-03 |
Jefferies | Upgraded | Hold → Buy | 2025-11-07 |
RBC Capital | Downgraded | Outperform → Sector Perform | 2025-11-05 |
RBC Capital Mkts | Downgraded | Outperform → Sector Perform | 2025-11-05 |
Cantor Fitzgerald | Reiterated | Overweight | 2024-09-16 |
HC Wainwright & Co. | Reiterated | Buy | 2024-09-06 |
HC Wainwright& Co. | Reiterated | Buy | 2023-08-07 |
Oppenheimer | Downgraded | Outperform → Perform | 2022-11-04 |
SVB Leerink | Reiterated | Outperform | 2022-11-04 |
H.C. Wainwright | Reiterated | Buy | 2019-12-16 |
Raymond James | Reiterated | Outperform | 2019-03-20 |
Leerink Swann | Reiterated | Outperform | 2017-10-23 |
Seaport Global | Reiterated | Buy | 2017-10-06 |
Canaccord Genuity | Reiterated | Buy → Speculative Buy | 2017-09-13 |
Mackie Research | Reiterated | Speculative Buy → Buy | 2016-11-01 |
One row per institution, most recent rating